Advertisement
Advertisement
BNTC
Benitec Biopharma Inc. Common Stock
9.28
USDSponsored
-0.59
-5.98%
Nov 10, 15:58 UTC -5
Closed
After-Market
9.27
-0.01
-0.16%
Benitec Biopharma Inc. Common Stock (BNTC) Earnings
BNTC Earnings Reports
Positive Surprise Ratio
BNTC beat 10 of 22 last estimates.
45%
Next Report
In 2 Days
Date of Next Report
Nov 12, 2026
Estimate for Q1 27 (Revenue/ EPS)
--
/-$0.29
Implied change from Q4 26 (Revenue/ EPS)
--
/+11.54%
Implied change from Q1 26 (Revenue/ EPS)
--
/+31.82%
Benitec Biopharma Inc. Common Stock earnings per share and revenue
On Sep 14, 2026, BNTC reported earnings of -0.26 USD per share (EPS) for Q4 26, beating the estimate of -0.27 USD, resulting in a 5.59% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -8.53% price change (close before vs. close after earnings).
Looking ahead to Q1 27, 4 analysts forecast an EPS of -0.29 USD, with revenue projected to reach -- USD, implying an increase of 11.54% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Benitec Biopharma Inc. Common Stock's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Benitec Biopharma Inc. Common Stock reported EPS of -$0.26, beating estimates by 5.59%, and revenue of $0.00, 0% as expectations.
How did the market react to Benitec Biopharma Inc. Common Stock's Q4 2026 earnings?
The stock price moved down -8.53%, changed from $12.08 before the earnings release to $11.05 the day after.
When is Benitec Biopharma Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 12, 2026.
What are the forecasts for Benitec Biopharma Inc. Common Stock's next earnings report?
Based on 4
analysts, Benitec Biopharma Inc. Common Stock is expected to report EPS of -$0.29 and revenue of -- for Q1 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.